BioInvent International

CASI Pharmaceuticals Inc (NASDAQ:CASI) and BioInvent International AB announced preliminary efficacy data for BI-1206 in combination with rituximab in patients with relapsed/refractory (R/R) indolent Non-Hodgkin’s Lymphoma (iNHL) in the ongoing development program in China. The...